Potential for additional government spending on HIV/AIDS in 137 low-income and middle-income countries: an economic modelling study

被引:34
|
作者
Haakenstad, Annie [1 ]
Moses, Mark W. [2 ]
Tao, Tianchan [2 ]
Tsakalos, Golsum [2 ]
Zlavog, Bianca [2 ]
Kates, Jennifer [3 ]
Wexler, Adam [3 ]
Murray, Christopher J. L. [2 ]
Dieleman, Joseph L. [2 ]
机构
[1] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA
[2] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA
[3] Kaiser Family Fdn, San Francisco, CA USA
来源
LANCET HIV | 2019年 / 6卷 / 06期
基金
比尔及梅琳达.盖茨基金会;
关键词
SYSTEMATIC ANALYSIS; GLOBAL BURDEN; HEALTH; DISEASE;
D O I
10.1016/S2352-3018(19)30038-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Between 2012 and 2016, development assistance for HIV/AIDS decreased by 20.0%; domestic financing is therefore critical to sustaining the response to HIV/AIDS. To understand whether domestic resources could fill the financing gaps created by declines in development assistance, we aimed to track spending on HIV/AIDS and estimated the potential for governments to devote additional domestic funds to HIV/AIDS. Methods We extracted 8589 datapoints reporting spending on HIV/AIDS. We used spatiotemporal Gaussian process regression to estimate a complete time series of spending by domestic sources (government, prepaid private, and out-of-pocket) and spending category (prevention, and care and treatment) from 2000 to 2016 for 137 low-income and middle-income countries (LMICs). Development assistance data for HIV/AIDS were from Financing Global Health 2018, and HIV/AIDS prevalence, incidence, and mortality were from the Global Burden of Disease study 2017. We used stochastic frontier analysis to estimate potential additional government spending on HIV/AIDS, which was conditional on the current government health budget and other finance, economic, and contextual factors associated with HIV/AIDS spending. All spending estimates were reported in 2018 US$. Findings Between 2000 and 2016, total spending on HIV/AIDS in LMICs increased from $4.0 billion (95% uncertainty interval 2.9-6.0) to $19.9 billion (15.8-26.3), spending on HIV/AIDS prevention increased from $596 million (258 million to 1.3 billion) to $3.0 billion (1.5-5.8), and spending on HIV/AIDS care and treatment increased from $1.1 billion (458.1 million to 2.2 billion) to $7.2 billion (4.3-11.8). Over this time period, the share of resources sourced from development assistance increased from 33.2% (21.3-45.0) to 46.0% (34.2-57.0). Care and treatment spending per year on antiretroviral therapy varied across countries, with an IQR of $284-2915. An additional $12.1 billion (8.4-17.5) globally could be mobilised by governments of LMICs to finance the response to HIV/AIDS. Most of these potential resources are concentrated in ten middle-income countries (Argentina, China, Colombia, India, Indonesia, Mexico, Nigeria, Russia, South Africa, and Vietnam). Interpretation Some governments could mobilise more domestic resources to fight HIV/AIDS, which could free up additional development assistance for many countries without this ability, including many low-income, high-prevalence countries. However, a large gap exists between available financing and the funding needed to achieve global HIV/AIDS goals, and sustained and coordinated effort across international and domestic development partners is required to end AIDS by 2030. Copyright (C) 2019 The Author(s). Published by Elsevier Ltd.
引用
收藏
页码:E382 / E395
页数:14
相关论文
共 50 条
  • [31] Youth suicide prevention in low-income and middle-income countries
    Robinson, Jo
    Krysinska, Karolina
    LANCET CHILD & ADOLESCENT HEALTH, 2019, 3 (04): : 200 - 201
  • [32] A look at spirometric PRISm in low-income and middle-income countries
    Obaseki, Daniel
    Bime, Christian
    Awopeju, Olayemi
    LANCET GLOBAL HEALTH, 2024, 12 (09): : e1379 - e1380
  • [33] Oral and Maxillofacial Surgery in Low-Income and Middle-Income Countries
    Lee, Jessica S.
    Roser, Steven M.
    Aziz, Shahid R.
    ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA, 2020, 32 (03) : 355 - +
  • [34] Screening and diagnosis of HBV in low-income and middle-income countries
    Allain, Jean-Pierre
    Opare-Sem, Ohene
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2016, 13 (11) : 643 - 653
  • [35] Paediatric pain management in low-income and middle-income countries
    Tang, Swee Ping
    Yeo, Angela S. H.
    Cardosa, Mary Suma
    LANCET CHILD & ADOLESCENT HEALTH, 2021, 5 (01): : 5 - 7
  • [36] Rotavirus vaccine protection in low-income and middle-income countries
    Ramakrishnan, Girija
    Ma, Jennie Z.
    Haque, Rashidul
    Petri, William A., Jr.
    LANCET INFECTIOUS DISEASES, 2019, 19 (07): : 673 - 674
  • [37] Restrictive migration policies in low-income and middle-income countries
    Vijayasingham, Lavanya
    Rhule, Emma
    Asgari-Jirhandeh, Nima
    Allotey, Pascale
    LANCET GLOBAL HEALTH, 2019, 7 (07): : E843 - E844
  • [38] Professional medical associations in low-income and middle-income countries
    Azimova, Aigul
    Abdraimova, Aida
    Orozalieva, Gulzat
    Muratlieva, Elvira
    Heller, Olivia
    Loutan, Louis
    Beran, David
    LANCET GLOBAL HEALTH, 2016, 4 (09): : E606 - E607
  • [39] Acute liver failure in low-income and middle-income countries
    Vento, Sandro
    Cainelli, Francesca
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11): : 1035 - 1045
  • [40] Determinants of youth crime in low-income and middle-income countries
    Murray, Joseph
    Atilola, Olayinka
    LANCET CHILD & ADOLESCENT HEALTH, 2020, 4 (02): : 96 - 98